Next Article in Journal
Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity
Next Article in Special Issue
p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer
Previous Article in Journal
Short-Term Microgravity Influences Cell Adhesion in Human Breast Cancer Cells
Previous Article in Special Issue
Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives
Review

Melanoma and Vitiligo: In Good Company

1
Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy
2
Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy
3
1st Dermatology Division, IDI-IRCCS, 00167 Rome, Italy
4
Molecular Oncology Laboratory, IDI-IRCCS, 00167 Rome, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(22), 5731; https://doi.org/10.3390/ijms20225731
Received: 14 October 2019 / Revised: 10 November 2019 / Accepted: 13 November 2019 / Published: 15 November 2019
(This article belongs to the Special Issue Skin Cancer: From Pathophysiology to Novel Therapeutic Approaches)
Cutaneous melanoma represents the most aggressive form of skin cancer, whereas vitiligo is an autoimmune disorder that leads to progressive destruction of skin melanocytes. However, vitiligo has been associated with cutaneous melanoma since the 1970s. Most of the antigens recognized by the immune system are expressed by both melanoma cells and normal melanocytes, explaining why the autoimmune response against melanocytes that led to vitiligo could be also present in melanoma patients. Leukoderma has been also observed as a side effect of melanoma immunotherapy and has always been associated with a favorable prognosis. In this review, we discuss several characteristics of the immune system responses shared by melanoma and vitiligo patients, as well as the significance of occurrence of leukoderma during immunotherapy, with special attention to check-point inhibitors. View Full-Text
Keywords: melanoma; autoimmunity; prognostic markers melanoma; autoimmunity; prognostic markers
Show Figures

Figure 1

MDPI and ACS Style

Failla, C.M.; Carbone, M.L.; Fortes, C.; Pagnanelli, G.; D’Atri, S. Melanoma and Vitiligo: In Good Company. Int. J. Mol. Sci. 2019, 20, 5731. https://doi.org/10.3390/ijms20225731

AMA Style

Failla CM, Carbone ML, Fortes C, Pagnanelli G, D’Atri S. Melanoma and Vitiligo: In Good Company. International Journal of Molecular Sciences. 2019; 20(22):5731. https://doi.org/10.3390/ijms20225731

Chicago/Turabian Style

Failla, Cristina M., Maria L. Carbone, Cristina Fortes, Gianluca Pagnanelli, and Stefania D’Atri. 2019. "Melanoma and Vitiligo: In Good Company" International Journal of Molecular Sciences 20, no. 22: 5731. https://doi.org/10.3390/ijms20225731

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop